Amisulpride interactions
Full monograph for AmisulprideCheck it against another medicine
Medicines
301 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abiraterone Acetate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Adenosine | Major | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 17 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide | Major | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 17 sources — open the full entry |
| Alfuzosin Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Amitriptyline Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Apalutamide | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Synergy | Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 16 sources — open the full entry |
| Asenapine Maleate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Atomoxetine Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Bicalutamide | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Bromocriptine Mesylate | Major | Antagonism | Agents with central antidopaminergic activity such as amisulpride may antagonize the pharmacologic effects of levodopa and other dopamine agonists, and vice… | 7 sources — open the full entry |
| Cabergoline | Major | Antagonism | Agents with central antidopaminergic activity such as amisulpride may antagonize the pharmacologic effects of levodopa and other dopamine agonists, and vice… | 7 sources — open the full entry |
| Cabozantinib | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Major | Antagonism | Agents with central antidopaminergic activity such as amisulpride may antagonize the pharmacologic effects of levodopa and other dopamine agonists, and vice… | 7 sources — open the full entry |
| Ceritinib | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Chloroquine Phosphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Chlorpromazine Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Cilostazol | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clarithromycin | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Clomipramine Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Clozapine | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Crizotinib | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Dasatinib | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Daunorubicin | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Degarelix Acetate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Deutetrabenazine | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Doxepin (Oral) | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Doxepin (Topical) | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Doxorubicin Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Efavirenz | Major | Metabolism | Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming… | 6 sources — open the full entry |
| Enzalutamide | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Epirubicin Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Eribulin Mesylate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| ErythromycinLotionOral | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Flecainide Acetate | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Fluoxetine Hydrochloride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
Conditions
Conditions in which Amisulpride needs care, as documented in this source.
Kidney Diseases
ModerateThe pharmacokinetics of amisulpride in patients with severe renal impairment have not been adequately studied, however, the drug is known to be substantially excreted by the kidneys and patients with severe renal impairment may have an increased risk of adverse reactions. Avoid the use in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2). No dosage adjustment is necessary in patients with mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 and above).
1 source
- "Product Information. Barhemsys (amisulpride)." Acacia Pharma, Inc (2020):
Long QT Syndrome
ModerateAmisulpride causes dose and concentration-dependent prolongation of the QT interval and should be avoided in patients with congenital long QT syndrome and in patients taking some drugs that prolong the QT interval such as droperidol. ECG monitoring is recommended in patients with pre-existing arrhythmias and cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products or with other medical conditions known to prolong the QT interval.
1 source
- "Product Information. Barhemsys (amisulpride)." Acacia Pharma, Inc (2020):
Therapeutic duplication
Drug classes that overlap with Amisulpride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antipsychotics
The recommended maximum number of medicines in the 'antipsychotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antipsychotics' category.
Example product in the source data (US market): Fluoxetine/olanzapine
antipsychotics
The recommended maximum number of medicines in the 'antipsychotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antipsychotics' category.
Example product in the source data (US market): Olanzapine/samidorphan
antipsychotics
The recommended maximum number of medicines in the 'antipsychotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antipsychotics' category.
Example product in the source data (US market): Amitriptyline/perphenazine